Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 8, 2009, Pages 765-770

  Braga Silva, L A ^a   Mesquita, D G A ^a   Ribeiro, M D ^a,b   Carvalho, S M F ^b   Fracalanzza, S E L ^a   Santos, A L S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HEMORIO   (Brazil)

Author keywords

Candida albicans; Sap2; Secreted aspartyl peptidases; Trailing growth

Indexed keywords

ASPARTYL PEPTIDASE; FLUCONAZOLE; HYDROLASE; ITRACONAZOLE; PEPSTATIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE TRANSMISSION; ENZYME ACTIVITY; FLOW CYTOMETRY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS ISOLATION; IMMUNE RESPONSE; IN VITRO STUDY; MICROBIAL METABOLISM; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; WESTERN BLOTTING;

CANDIDA ALBICANS;

EID: 70349486931     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000800013     Document Type: Article

References (29)

1. Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23: 323-330.
2. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857-863.
3. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001; 9: 327-335.
4. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67: 400-428.
5. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-788.
6. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495-2497.
7. Pfaller MA, Lockhart SR, Pujol C, Swails-Wenger JA, Messer SA, Edmond MB, et al. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microbiol 1998; 36: 1518-1529.
8. Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002; 50: 999-1002.
9. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 1997; 41: 535-539.
10. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 2001; 45: 52-59.
11. Ollert MW, Wende C, Gorlich M, Mullan-Vogel CG, Borg-von Zepelin M, Vogel CW, et al. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol 1995; 33: 2543-2549.
12. Ozkan S, Kaynak F, Kalkanci A, Abbasoglu U, Kustimur S. Slime production and proteinase activity of Candida species isolated from blood samples and the comparison of these activities with minimum inhibitory concentration values of antifungal agents. Mem Inst Oswaldo Cruz 2005; 100: 319-323.
13. Ribeiro MD. Análise comparativa por diferentes metodologias do perfil de susceptibilidade aos antifúngicos de leveduras isoladas de espécimes clínicos. [Master's thesis]: Instituto de Microbiologia Prof. Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; 2006.
14. Yang YL, Cheng HH, Ho YA, Hsiao CF, Lo HJ. Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. J Microbiol Immunol Infect 2003; 36: 187-191.
15. Clinical and Laboratory Standards Institute (formerly NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts. Wayne: Approved Standard. M27A; 1997.
16. White TC, Agabian N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 1995; 177: 5215-5221.
17. Santos ALS, Carvalho I, Silva BA, Portela MB, Alviano CS, Soares RMA. Secretion of serine peptidase by a clinical strain of Candida albicans: influence of growth conditions and cleavage of human serum proteins and extracellular matrix components. FEMS Immunol Med Microbiol 2006; 46: 209-220.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
19. Buroker-Kilgore M, Wang KK. A Coomassie brilliant blue G-250-based colorimetric assay for measuring activity of calpain and other proteases. Anal Biochem 1993; 208: 387-392.
20. Silva BA, Pinto MR, Soares RMA, Barreto-Bergter E, Santos ALS. Pseudallescheria boydii releases metallopeptidases capable of cleaving several proteinaceous compounds. Res Microbiol 2006; 157: 425-432.
21. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-785.
22. Aperis G, Myriounis N, Spanakis EK, Mylonakis E. Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs 2006; 15: 1319-1336.
23. Portela MB, Souza IP, Costa EM, Hagler AN, Soares RMA, Santos ALS. Differential recovery of Candida species from subgingival sites in human immunodeficiency virus-positive and healthy children from Rio de Janeiro, Brazil. J Clin Microbiol 2004; 42: 5925-5927.
24. Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217-224.
25. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-3154.
26. Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002; 46: 3532-3539.
27. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.
28. Smolenski G, Sullivan PA, Cutfield SM, Cutfield JF. Analysis of secreted aspartic proteinases from Candida albicans: purification and characterization of individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology 1997; 143 (Part 2): 349-356.
29. De Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schafer W, et al. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201-208.